title: [Combination chemotherapy with BH-AC, mitoxantrone, etoposide, and prednisolone to refractory or relapsed malignant lymphoma].
authors.affiliation: First Dept. of Internal Medicine, Hirosaki University School of Medicine.
authors.forename: T
authors.initials: T
authors.lastname: Satoh
authors.forename: K
authors.initials: K
authors.lastname: Tsushima
authors.forename: Y
authors.initials: Y
authors.lastname: Hizawa
authors.forename: Y
authors.initials: Y
authors.lastname: Nakui
authors.forename: J
authors.initials: J
authors.lastname: Itoh
authors.forename: Y
authors.initials: Y
authors.lastname: Tamura
authors.forename: S
authors.initials: S
authors.lastname: Saitoh
authors.forename: H
authors.initials: H
authors.lastname: Taka-mi
authors.forename: A
authors.initials: A
authors.lastname: Munakata
authors.forename: S
authors.initials: S
authors.lastname: Kawamura
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D016399:Lymphoma, T-Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D011239:Prednisolone / Q000008:administration & dosage
chemical_list: D003561:Cytarabine; D005047:Etoposide; D011239:Prednisolone; C015019:enocitabine; D008942:Mitoxantrone